Synergy CHC Corp. (SNYR) 股票分析

公司概述

Synergy CHC Corp. operates within the healthcare sector, specifically focusing on the medical distribution industry by supplying consumer health care, beauty, and lifestyle products across the United States, Canada, and the United Kingdom. The company's product portfolio includes brain health nutritional supplements marketed under the FOCUSfactor brand, alongside various wellness items such as tea, shakes, and lollipops. With a market capitalization of $7.25M and annual revenue of $30.38M, the company represents a small-cap entity with limited operational scale compared to major industry peers. The absence of employee count data in public filings suggests either a streamlined workforce or a reporting structure where headcount is not publicly disclosed, which often characterizes smaller private or publicly traded firms in niche distribution markets. These valuation metrics indicate that the company holds a modest position in the market, relying on a specific set of niche products rather than broad-scale manufacturing or massive distribution networks to generate its revenue stream.

财务健康

The company reported a trailing twelve-month revenue of $30.38M, yet this generated a net income of $-12,341,208, revealing a highly distressed cost structure where operating expenses significantly exceed gross profits. EBITDA stands at $-8,325,415, further confirming that the business is currently operating at a loss before financing and non-cash items, which is typical for companies in a restructuring phase or facing intense margin compression. Despite the accounting losses, the firm maintains positive free cash flow of $2.04M, indicating that the core operations generate sufficient cash to cover capital expenditures and potentially service debt or pay down liabilities. The balance sheet shows a cash balance of $2.62M against total debt of $26.81M, highlighting a leveraged position where debt obligations substantially exceed liquid assets. The debt-to-equity ratio is not available, but the negative price-to-book ratio of -0.87 suggests that the market values the company well below its book value, often seen in distressed assets. Liquidity is constrained with a current ratio of 1.22, meaning current assets only cover current liabilities 1.22 times over, leaving little room for error in short-term solvency. Return on Equity is not available due to equity distortions, while return on assets is -39.9%, demonstrating that management is currently generating negative returns on the capital base employed.

估值评估

Valuation multiples reflect the company's earnings challenges, with a trailing P/E ratio of N/A due to negative earnings and a forward P/E of 1.08, which implies that the market expects earnings to recover significantly to justify even a single multiple of future earnings. The price-to-book ratio is -0.87, indicating that the stock trades at a deep discount to its book value, a metric that typically signals market skepticism regarding the quality of the company's assets or the sustainability of its operations. Alternative valuation measures such as a price-to-sales ratio of 0.24 and an EV/EBITDA of -3.78 suggest that investors are pricing the stock based on revenue generation potential rather than profitability, as negative EV/EBITDA precludes traditional earnings-based comparisons. Price action shows significant volatility, with the 52-week high at $4.08 and the 52-week low at $0.64; without the exact current price, the stock is trading within a range that spans a 634% swing from its lowest point. The beta of 1.47 indicates that the stock's price volatility is 47% higher than the broader market, making it a high-risk investment that reacts more sharply to market movements than large-cap equities.

Growth & Income

Revenue growth year-over-year is -41.0%, while earnings growth year-over-year is N/A due to the negative net income, implying that the company is currently in a contraction phase rather than an expansionary growth stage. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available earnings, if any, are theoretically retained or the company lacks earnings to distribute. Given the negative earnings and lack of a dividend history, the company is not reinvesting earnings into growth in the traditional sense but rather is likely preserving cash to address its negative operating margins and debt obligations. The overall growth and income profile is characterized by significant revenue contraction, negative profitability, and a total absence of income distribution to shareholders, presenting a challenging outlook for income-focused investors.